2/10
06:00 am
psnl
Personalis Receives Medicare Coverage for NeXT Personal® in Lung Cancer Surveillance
High
Report
Personalis Receives Medicare Coverage for NeXT Personal® in Lung Cancer Surveillance
2/2
08:36 pm
psnl
Personalis, Inc. (PSNL): A Bull Case Theory [Yahoo! Finance]
Medium
Report
Personalis, Inc. (PSNL): A Bull Case Theory [Yahoo! Finance]
2/2
06:24 am
psnl
Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors [Yahoo! Finance]
Low
Report
Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors [Yahoo! Finance]
2/2
06:00 am
psnl
Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors
Low
Report
Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors
1/28
04:01 pm
psnl
Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Low
Report
Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
1/26
10:02 am
psnl
Personalis (NASDAQ:PSNL) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
Personalis (NASDAQ:PSNL) had its "buy" rating reaffirmed by analysts at Guggenheim.
1/12
04:39 pm
psnl
Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™ [Yahoo! Finance]
Low
Report
Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™ [Yahoo! Finance]
1/12
04:00 pm
psnl
Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™
Low
Report
Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™
1/9
08:02 am
psnl
Personalis (NASDAQ:PSNL) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $12.00 price target on the stock.
Medium
Report
Personalis (NASDAQ:PSNL) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $12.00 price target on the stock.
1/8
08:00 am
psnl
Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights
Medium
Report
Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights
1/3
01:08 am
psnl
12/30
12:42 pm
psnl
Morgan Stanley Analyst Initiates Equal Weight Rating On Personalis, Inc. (PSNL) [Yahoo! Finance]
Low
Report
Morgan Stanley Analyst Initiates Equal Weight Rating On Personalis, Inc. (PSNL) [Yahoo! Finance]
12/17
06:37 am
psnl
Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors [Yahoo! Finance]
Medium
Report
Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors [Yahoo! Finance]
12/17
06:00 am
psnl
Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors
Medium
Report
Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors
12/14
01:26 am
psnl
Medium
Report
12/11
09:00 am
psnl
New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer
Low
Report
New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer
12/11
07:14 am
psnl
Why Analysts See Personalis Story Shifting With Medicare Tailwinds And Biopharma Headwinds [Yahoo! Finance]
Low
Report
Why Analysts See Personalis Story Shifting With Medicare Tailwinds And Biopharma Headwinds [Yahoo! Finance]
12/1
07:02 pm
psnl
Personalis (NASDAQ:PSNL) was given a new $11.00 price target on by analysts at Morgan Stanley.
Low
Report
Personalis (NASDAQ:PSNL) was given a new $11.00 price target on by analysts at Morgan Stanley.
11/27
10:37 pm
psnl
Personalis: A Growth Inflection Is Imminent, Hold [Seeking Alpha]
Low
Report
Personalis: A Growth Inflection Is Imminent, Hold [Seeking Alpha]
11/18
04:01 pm
psnl
Personalis to Participate in the Piper Sandler 37th Annual Healthcare Conference
Medium
Report
Personalis to Participate in the Piper Sandler 37th Annual Healthcare Conference